Molecular and Clinicopathologic Characterization of Intravenous Leiomyomatosis

Intravenous leiomyomatosis (IVL) is an unusual uterine smooth muscle proliferation that can be associated with aggressive clinical behavior despite a histologically benign appearance. It has some overlapping molecular characteristics with both uterine leiomyoma and leiomyosarcoma based on limited genetic data. In this study, we assessed the clinical and morphological characteristics of 28 IVL and their correlation with molecular features and protein expression, using array comparative genomic hybridization (aCGH) and Cyclin D1, p16, phosphorylated-Rb, SMARCB1, SOX10, CAIX, SDHB and FH immunohistochemistry. The most common morphologies were cellular (n=15), usual (n=11) and vascular (n=5; including 3 cellular IVL showing both vascular and cellular features). Among the immunohistochemical findings, the most striking was that all IVL showed differential expression of either p16 or Cyclin D1 in comparison to surrounding non-neoplastic tissue. Cytoplasmic phosphorylated-Rb was present in all but one IVL with hyalinization. SMARCB1, FH and SDHB were retained; S0X10 and CAIX were not expressed. The most common genetic alterations involved 1p (39%), 22q (36%), 2q (29%), 1q (25%), 13q (21%) and 14q (21%). Hierarchical clustering analysis of recurrent aberrations revealed 3 molecular groups: Group 1 (29%) and 2 (18%) with associated del(22q) and group 3 (18%) with del(10q). The remaining IVL had non-specific or no alterations by aCGH. Genomic index scores were calculated for all cases and showed no significant difference between the 14 IVL associated with aggressive clinical behavior (extrauterine extension or recurrence) and those without (median scores 5.15 vs 3.5). Among the 5 IVL associated with recurrence, 4 had a vascular morphology and 3 had alterations of 8q. Recurrent chromosome alterations detected herein overlap with those observed in the spectrum of uterine smooth muscle tumors and involve genes implicated in mesenchymal tumors at different sites with distinct morphological features

SNPs Array Karyotyping Reveals a Novel Recurrent 20p13 Amplification in Primary Myelofibrosis

The molecular pathogenesis of primary mielofibrosis (PMF) is still largely unknown. Recently, single-nucleotide polymorphism arrays (SNP-A) allowed for genome-wide profiling of copy-number alterations and acquired uniparental disomy (aUPD) at high-resolution. In this study we analyzed 20 PMF patients using the Genome-Wide Human SNP Array 6.0 in order to identify novel recurrent genomic abnormalities. We observed a complex karyotype in all cases, detecting all the previously reported lesions (del(5q), del(20q), del(13q), +8, aUPD at 9p24 and abnormalities on chromosome 1). In addition, we identified several novel cryptic lesions. In particular, we found a recurrent alteration involving cytoband 20p13 in 55% of patients. We defined a minimal affected region (MAR), an amplification of 9,911 base-pair (bp) overlapping the SIRPB1 gene locus. Noteworthy, by extending the analysis to the adjacent areas, the cytoband was overall affected in 95% of cases. Remarkably, these results were confirmed by real-time PCR and validated in silico in a large independent series of myeloproliferative diseases. Finally, by immunohistochemistry we found that SIRPB1 was over-expressed in the bone marrow of PMF patients carrying 20p13 amplification. In conclusion, we identified a novel highly recurrent genomic lesion in PMF patients, which definitely warrant further functional and clinical characterization

Prevalence of hr‐HPV genotypes among vaccinated and unvaccinated women in central Italy: a retrospective study

Background and aim: Human papillomavirus is the most common sexually transmitted infection worldwide. Data on the prevalence of genital HPV infection are heterogeneous since the risk of infection and the gravity of diseases is depending by geography, socioeconomic conditions, assessed population. In the present study, it was evaluated the prevalence of high-risk HPV genotypes in women who have attended at a diagnostic laboratory in the Marche region (Italy) for cervical cancer test. Methods: Pap tests and biomolecular analyses were conducted in 875 women for the identification of hr-HPV genotypes and common concomitant infections of the genital tract. Multiplex Real-time PCR was used for the simultaneous identification of hr-HPV 16, 18, and non-specified pooled detection of HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68. Results: Of 875 women tested, 228 (26%) resulted hr-HPV positive, with a higher prevalence (28%) in the range of 35-44 years. In the unvaccinated group,the prevalence of infection was about 5 times higher vs. vaccinated women. The hr-HPV16 was the most diagnosed genotype, followed by hr-HPV18. The high-grade cytological abnormalities were identified only in unvaccinated women. Finally, 71 % of hr-HPV infections were concomitant with other infections of the genital tract. Conclusions: A meaningful diffusion of hr-HPV, prevalently genotypes HPV-16, was observed in women > 25 years, frequently associated with other sexually transmitted infections, and a substantial difference in the risk of cervical cancer in unvaccinated compared to vaccinated women. The enhancement of primary and secondary prevention interventions must be further incentivized

Methodological Framework

The EUARENAS Conceptual framework (D1.1) retraces the theories on democratic deliberation and establishes a common conceptual framework. Work Package 2 (WP2) – Methodology – is related to this context and charged with the objective of establishing a methodological framework that is appropriate to overcome the challenge of ensuring diversity and inclusivity and to increase the effectiveness and outcomesof the urban experimentations under an ethical and justice perspective. While the task of delivering a methodological protocol that is unbiased, respectful of ethical principles and guidelines as well as able to ensure justice as an outcome of the urban experimentations is on Deliverable 2.2. Methodological protocol,this report will start delving into the issue by reviewing the families of theories on participatory and deliberative democracy through the lens of urban diversity, inclusiveness and justice. This report is focused on a literature review of existing academic research and policy debate on problem- based urban research of an empirical and applied nature. It is structured in four main parts: literature review; presentation of the proposed methodological model; contextualization of the theme of social and urban impact measurement in the light of an experimental ethical, inclusive and collaborative approach; summaryof the working method and tools for co-design

Expression pattern alterations of the serine protease HtrA1 in normal human placental tissues and in gestational trophoblastic diseases

HtrA1 is a secreted protein which behaves as a molecular chaperone at low temperatures and as a serine protease at high temperatures. When the placenta escapes the normal growth control mechanisms, which are present during normal pregnancy, it may develop trophoblastic diseases, such as hydatidiform mole and choriocarcinoma. The aim of the study is to investigate the expression of HtrA1 in these gestational trophoblastic diseases and evaluate whether different HtrA1 expression might be associated with increasingly severe forms of disease. We used immunohistochemistry to assess the expression of HtrA1 in normal human placenta, hydatidiform mole (partial and complete) and choriocarcinoma. In addition to that we used the western blotting technique to quantify HtrA1 immunoreaction in normal human placentas. The most striking finding of our investigation is the decrease in immunostaining of this protease with increasing severity of gestational trophoblastic disease. For instance, in partial and complete moles HtrA1 is weakly expressed in the trophoblast. Moreover, absence of immunoreaction for HtrA1 is observable in the choriocarcinoma cells. In conclusion, we suggest that HtrA1 may play an important role in the pathogenesis and progression of hydatidiform moles and choriocarcinomas, and that HtrA1 may play an important role during the normal development of the placenta, as well as in trophoblastic diseases

Histopathologic Prognostic Factors in Stage I Leiomyosarcoma of the Uterus: A Detailed Analysis of 27 Cases.

Uterine leiomyosarcomas (Ut-LMSs) are aggressive tumors with an overall poor prognosis (15% to 25% 5-year survival rate). However, patients with stage I Ut-LMSs are reported to have a relatively better outcome when compared with the overall group with a 5-year survival rate ranging from 25% to 75%. The purpose of this study was to evaluate the histopathologic parameters that may impact outcome in stage I Ut-LMSs. Twenty-seven patients with stage I Ut-LMSs were identified from the files of 5 tertiary care hospitals between 1974 and 2006. Tumors were primarily staged based on pathologic information, supplemented with radiologic findings (10 cases) and clinical records (1 case). Patients with stage I tumors with no additional clinical or radiologic staging information were included in the study if no recurrence was documented after 6 months from the initial staging operation (16 cases). Clinicopathologic parameters that were statistically evaluated included age [mean, 54 y (37 to 73)], tumor size [mean, 9.5 cm (5.5 to 16)], cell type (17 spindled, 5 epithelioid, 2 myxoid, and 3 mixed), mitotic activity [mean count, 24 (4 to 69)/10 high-power fields], marked cytologic atypia (26 of 27 cases), tumor cell necrosis (12 of 27 cases), and lymphovascular invasion (6 of 27 cases). Follow-up was available for all the patients. Poor outcome was defined when patients either died of disease or were alive with disease. Overall, accounting for any length of follow-up, 16 of 27 (59%) patients with stage I Ut-LMSs had poor outcome; 7 died of disease (mean follow-up, 13 mo) and 9 were alive with disease (mean follow-up, 31 mo). The remaining 11 patients were alive and well with a mean follow-up of 48 months. However, at 2 years of follow-up by univariate analysis, only nonspindle morphology (

Molecular and Clinicopathologic Characterization of Intravenous Leiomyomatosis

Intravenous leiomyomatosis (IVL) is an unusual uterine smooth muscle proliferation that can be associated with aggressive clinical behavior despite a histologically benign appearance. It has some overlapping molecular characteristics with both uterine leiomyoma and leiomyosarcoma based on limited genetic data. In this study, we assessed the clinical and morphological characteristics of 28 IVL and their correlation with molecular features and protein expression, using array comparative genomic hybridization (aCGH) and Cyclin D1, p16, phosphorylated-Rb, SMARCB1, SOX10, CAIX, SDHB and FH immunohistochemistry. The most common morphologies were cellular (n=15), usual (n=11) and vascular (n=5; including 3 cellular IVL showing both vascular and cellular features). Among the immunohistochemical findings, the most striking was that all IVL showed differential expression of either p16 or Cyclin D1 in comparison to surrounding non-neoplastic tissue. Cytoplasmic phosphorylated-Rb was present in all but one IVL with hyalinization. SMARCB1, FH and SDHB were retained; S0X10 and CAIX were not expressed. The most common genetic alterations involved 1p (39%), 22q (36%), 2q (29%), 1q (25%), 13q (21%) and 14q (21%). Hierarchical clustering analysis of recurrent aberrations revealed 3 molecular groups: Group 1 (29%) and 2 (18%) with associated del(22q) and group 3 (18%) with del(10q). The remaining IVL had non-specific or no alterations by aCGH. Genomic index scores were calculated for all cases and showed no significant difference between the 14 IVL associated with aggressive clinical behavior (extrauterine extension or recurrence) and those without (median scores 5.15 vs 3.5). Among the 5 IVL associated with recurrence, 4 had a vascular morphology and 3 had alterations of 8q. Recurrent chromosome alterations detected herein overlap with those observed in the spectrum of uterine smooth muscle tumors and involve genes implicated in mesenchymal tumors at different sites with distinct morphological features

Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the progression of colorectal cancer (CRC)

Background: Cancer cells reprogram their metabolism to meet specific bioenergetic/biosynthetic needs. Abnormal expression of energy metabolism enzymes may sustain aggressive phenotypes, therapeutic resistance and it may disclose novel therapeutic targets. We analyzed mRNA expression of glucose metabolism, key-enzyme genes in normal mucosa (NM), primary tumor (PT) and liver metastasis (LM) of CRC patients (pts) who underwent surgery and systemic therapy for advanced disease. Methods: Tissues of chemotherapy-naive, non-diabetic CRC pts were retrospectively studied by RT-qPCR for mRNA expression of the following genes: hexokinase-1 (HK1) and 2 (HK2), embryonic pyruvate kinase (PKM2), lactate dehydrogenase-A (LDH-A),glucose transporter-1 (SLC2A), voltage-dependent anion-selective channel protein-1 (VDAC1). The RT-qPCR ΔCt values (Cttarget–Ctreference) were used for calculating the expression level of each target gene with B2M and GUSB adopted as reference genes. A preliminary assessment was planned in a random sample of 24/72 enrolled pts (33%) to verify whether differences were detectable. T-test (Tt) and Wilcoxon test (Wt) were used for comparing ΔCt values between tissues (PT versus NM, LM versus NM, PT versus LM). Results: In the 24 pts, assays repeated with B2M and GUSB showed higher PT mRNA expression than NM for HK1 (Tt p = 0.0001; Wt p = 0.0004), LDH-A (Tt p < 0.0001, Wt p < 0.0001), PKM2 (Tt p < 0.0001, Wt p < 0.0001), SCL2A (Tt p < 0.0001, Wt p < 0.0001), VDAC1(Tt p = 0.0002, Wt p = 0.0004). The same significant associations were found when comparing LM versus NM tissues. There was a trend for higher mRNA expression of these genes in LM than in PT, but at this stage differences did not reach statistical significance. Conclusions: These results indicate enhanced glucose uptake (SCL2A, HK), glycolysis (LDH, PKM2) and mithocondrial trafficking (VDAC1) in CRC. Final analysis will include correlations with RAS/RAF mutational status and survival outcomes